<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01531361</url>
  </required_header>
  <id_info>
    <org_study_id>2011-1183</org_study_id>
    <secondary_id>NCI-2012-00217</secondary_id>
    <secondary_id>2011-1183</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT01531361</nct_id>
  </id_info>
  <brief_title>Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations</brief_title>
  <official_title>A Phase I Trial of Sorafenib (CRAF, BRAF, KIT, RET, VEGFR, PDGFR Inhibitor) or Crizotinib (MET, ALK, ROS1 Inhibitor) in Combination With Vemurafenib (BRAF Inhibitor) in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I clinical trial studies vemurafenib with sorafenib tosylate or crizotinib in&#xD;
      treating patients with advanced malignancies with BRAF mutations. Sorafenib tosylate and&#xD;
      crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for&#xD;
      cell growth. Sorafenib tosylate may also stop the growth of advanced malignancies by blocking&#xD;
      blood flow to tumors. Drugs used in chemotherapy, such as vemurafenib, work in different ways&#xD;
      to stop the growth of cancer cells, either by killing the cells, by stopping them from&#xD;
      dividing, or by stopping them from spreading. Giving vemurafenib together with sorafenib&#xD;
      tosylate or crizotinib may kill more cancer cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of&#xD;
      sorafenib tosylate (sorafenib) or crizotinib in combination with vemurafenib in patients with&#xD;
      advanced cancers who progressed on standard therapy.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Preliminary assessment of antitumor efficacy of sorafenib or crizotinib combination with&#xD;
      vemurafenib in patients with advanced cancers.&#xD;
&#xD;
      II. Preliminary assessment of the pharmacokinetic (PK) profile of sorafenib or crizotinib in&#xD;
      combination with vemurafenib.&#xD;
&#xD;
      III. Preliminary assessment of biomarkers.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of vemurafenib and sorafenib tosylate. Patients are&#xD;
      assigned to 1 of 2 treatment arms by their physician.&#xD;
&#xD;
      ARM I: Patients receive vemurafenib orally (PO) twice daily (BID) and sorafenib tosylate PO&#xD;
      BID on days 1-28.&#xD;
&#xD;
      ARM II: Patients receive vemurafenib as in Arm I and crizotinib PO once daily (QD) or BID on&#xD;
      days 1-28.&#xD;
&#xD;
      In both arms, courses repeat every 28 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 6, 2012</start_date>
  <completion_date type="Actual">January 13, 2021</completion_date>
  <primary_completion_date type="Actual">January 13, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of vemurafenib and sorafenib tosylate or crizotinib, defined as the highest dose studied in which the incidence of dose limiting toxicity was less than 33%</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Advanced Malignant Neoplasm</condition>
  <condition>BRAF Gene Mutation</condition>
  <condition>Metastatic Malignant Neoplasm</condition>
  <condition>Recurrent Malignant Neoplasm</condition>
  <condition>Refractory Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Arm I (vemurafenib and sorafenib tosylate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive vemurafenib PO BID and sorafenib tosylate PO BID on days 1-28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (vemurafenib and crizotinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive vemurafenib as in Arm I and crizotinib PO QD or BID on days 1-28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crizotinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (vemurafenib and crizotinib)</arm_group_label>
    <other_name>MET Tyrosine Kinase Inhibitor PF-02341066</other_name>
    <other_name>PF-02341066</other_name>
    <other_name>PF-2341066</other_name>
    <other_name>Xalkori</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (vemurafenib and sorafenib tosylate)</arm_group_label>
    <arm_group_label>Arm II (vemurafenib and crizotinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (vemurafenib and sorafenib tosylate)</arm_group_label>
    <arm_group_label>Arm II (vemurafenib and crizotinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib Tosylate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (vemurafenib and sorafenib tosylate)</arm_group_label>
    <other_name>BAY 43-9006 Tosylate</other_name>
    <other_name>BAY 54-9085</other_name>
    <other_name>Nexavar</other_name>
    <other_name>sorafenib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vemurafenib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (vemurafenib and sorafenib tosylate)</arm_group_label>
    <arm_group_label>Arm II (vemurafenib and crizotinib)</arm_group_label>
    <other_name>BRAF (V600E) kinase inhibitor RO5185426</other_name>
    <other_name>BRAF(V600E) Kinase Inhibitor RO5185426</other_name>
    <other_name>PLX-4032</other_name>
    <other_name>PLX4032</other_name>
    <other_name>RG 7204</other_name>
    <other_name>RG7204</other_name>
    <other_name>RO 5185426</other_name>
    <other_name>Zelboraf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with advanced or metastatic cancers and BRAF mutations that are refractory to&#xD;
             standard therapy, relapsed after standard therapy, or who have no standard therapy&#xD;
             available that improves survival by at least three months; patients with BRAF mutation&#xD;
             in cell free deoxyribonucleic acid (DNA) (tested in Clinical Laboratory Improvement&#xD;
             Amendments [CLIA] lab) are also eligible&#xD;
&#xD;
          -  Patients must be &gt;= 3 weeks beyond treatment with a cytotoxic chemotherapy regimen, or&#xD;
             therapeutic radiation, or major surgery; patients may have received palliative&#xD;
             localized radiation immediately before or during treatment provided that radiation is&#xD;
             not delivered to the only site of disease being treated under this protocol; for&#xD;
             biologic/targeted agents patients must be &gt;= 5 half-lives or &gt;= 3 weeks from the last&#xD;
             dose (whichever comes first); patients previously treated with vemurafenib monotherapy&#xD;
             do not have to stop medication before they start on the protocol&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1,000/mL&#xD;
&#xD;
          -  Platelets &gt;= 75,000/mL&#xD;
&#xD;
          -  Creatinine =&lt; 2 X upper limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin =&lt; 2 X ULN (exceptions may apply to benign non-malignant indirect&#xD;
             hyperbilirubinemia such as Gilbert syndrome)&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) and/or&#xD;
             aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =&lt; 5&#xD;
             X ULN&#xD;
&#xD;
          -  Exception for patients with liver metastasis: total bilirubin =&lt; 3 x ULN; ALT (SGPT)&#xD;
             =&lt; 8 X ULN&#xD;
&#xD;
          -  Dermatology evaluation with excision of any suspicious lesions prior to initiation of&#xD;
             therapy&#xD;
&#xD;
          -  Women of childbearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; abstinence) prior to study entry, for&#xD;
             the duration of study participation, and for 30 days after the last dose&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             within 2 weeks prior to initiation of therapy&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks in the opinion of the investigator&#xD;
&#xD;
          -  Patients must be able to understand and be willing to sign a written informed consent&#xD;
             document&#xD;
&#xD;
          -  Patient must be able to swallow pills&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled intercurrent illness, including, but not limited to, uncontrolled&#xD;
             infection, uncontrolled asthma, need for hemodialysis, need for ventilatory support&#xD;
&#xD;
          -  Syndrome of congenital corrected QT interval (QTc) prolongation or QTc &gt; 500 msec&#xD;
&#xD;
          -  Patients with clinically significant cardiovascular disease: history of&#xD;
             cerebrovascular accident (CVA) within 6 months, myocardial infarction or unstable&#xD;
             angina within 6 months, or unstable angina pectoris&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  History of hypersensitivity to vemurafenib&#xD;
&#xD;
          -  History of hypersensitivity to sorafenib for vemurafenib/sorafenib arm&#xD;
&#xD;
          -  History of hypersensitivity to crizotinib for vemurafenib/crizotinib arm&#xD;
&#xD;
          -  History of hypersensitivity to any component of the formulation&#xD;
&#xD;
          -  Patients unwilling or unable to sign informed consent document&#xD;
&#xD;
          -  Patients using any of the following medications: mesoridazine, dronedarone,&#xD;
             thioridazine, ziprasidone, levomethadyl, and saquinavir for vemurafenib/sorafenib arm&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filip Janku</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 6, 2012</study_first_submitted>
  <study_first_submitted_qc>February 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2012</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Vemurafenib</mesh_term>
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

